Table 2.

Phase II studies of erlotinib for Japanese patients with EGFR-mutated non-small-cell lung cancer

Study	Number of patients	Treatment line	EGFR mutational analyses	ORR (%)	Median PFS (months)	Reference
LOGiK0803	26	Second or third line	Exon 19 deletion or L858R PCR-based direct sequencing, invader assay, or clamp assay	53.8	9.3	26
JO22903	102	First line	Exon 19 deletion or L858R Scorpion ARMS	78.4	11.8	27

Abbreviations: ARMS, amplification refractory mutation system; ORR, objective response rate; PFS, progression-free survival; EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction.